TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
Pfizer Anti-Infectives AB
Closing information (x1000 NOK)
| Closing information | 2024/11 | 2023/11 | 2022/11 |
| Turnover |
1,852,112
|
2,168,842
|
1,280,955 |
| Financial expenses |
0
|
0
|
447 |
| Earnings before taxes |
1,099,006
|
1,036,241
|
392,998 |
| EBITDA |
1,032,752
|
1,069,283
|
449,477 |
| Total assets |
2,918,590
|
2,577,192
|
1,496,197 |
| Current assets |
99,962
|
68,280
|
106,356 |
| Current liabilities |
263,377
|
775,281
|
592,261 |
| Equity capital |
2,655,213
|
1,801,911
|
903,936 |
| - share capital |
51
|
51
|
47 |
| Employees (average) |
0
|
0
|
0 |
Financial ratios
| Fiscal year | 2024/11 | 2023/11 | 2022/11 |
| Solvency |
91.0%
|
69.9%
|
60.4% |
| Turnover per employee | |||
| Profit as a percentage of turnover |
59.3%
|
47.8%
|
30.7% |
| Return on assets (ROA) |
37.7%
|
40.2%
|
26.3% |
| Current ratio |
38.0%
|
8.8%
|
18.0% |
| Return on equity (ROE) |
41.4%
|
57.5%
|
43.5% |
| Change turnover |
-292,946
|
781,334
|
968,092 |
| Change turnover % |
-14%
|
56%
|
309% |
| Chg. No. of employees |
0
|
0
|
0 |
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2024/11 | 2023/11 | 2022/11 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.